Influenza
Start with the big picture
The lesson organizes influenza antivirals by mechanism. Neuraminidase inhibitors—oseltamivir, zanamivir, and peramivir—act against influenza A and B by limiting release of newly formed virus; the snapshot outlines their routes, uses, and distinguishing safety concerns. M2 ion-channel blockers inhibit uncoating but are not recommended because resistance among circulating influenza A strains is widespread. Baloxavir targets the cap-dependent endonuclease involved in viral replication and has its own timing, interaction, and resistance considerations. The material also reviews the role of early treatment, post-exposure prophylaxis, and antiviral therapy in reducing symptom duration and complications, with attention to higher-risk groups.
What you'll learn
- Explain how neuraminidase inhibitors limit the spread of influenza virus.
- Compare the mechanisms and clinical roles of neuraminidase inhibitors, M2 blockers, and baloxavir.
- Identify important adverse effects and resistance considerations for influenza antivirals.
- Describe the importance of treatment timing and post-exposure prophylaxis.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
